Wuxi Taiji Industry Limited Corporation(600667) pre bid for 1.229 billion yuan SMIC Shaoxing phase II wafer manufacturing project
Wuxi Taiji Industry Limited Corporation(600667) announcement: according to the announcement of bid winning candidates released by the China public service platform for bidding and tendering, the company’s subsidiary No. 11 technology is the first bid winning candidate for the factory process support system of SMIC Shaoxing phase II wafer manufacturing project (phase I), with a bid winning price of 1229000202 yuan.
The company released the performance express on the same day. In 2021, the company achieved a total operating revenue of 24266786400 yuan, a year-on-year increase of 35.98%; The net profit attributable to the shareholders of the listed company was 901286300 yuan, a year-on-year increase of 8.21%.
Hoshine Silicon Industry Co.Ltd(603260) it is proposed to invest 17.5 billion yuan in the construction of 200000 tons of high-purity polysilicon project
According to the announcement of Hoshine Silicon Industry Co.Ltd(603260) , the company plans to invest in the construction of the silicon-based new material industry integration project of Xinjiang central Hoshine Silicon Industry Co.Ltd(603260) Co., Ltd. (the high-purity polysilicon project with an annual output of 200000 tons), with an investment scale of 1.75 million yuan. The construction content of the project includes 200000 t / a polysilicon unit, 100000 t / a caustic soda unit, as well as supporting public works and auxiliary works. The construction period of the project is from May 2022 to may 2025.
Nanhua Futures Co.Ltd(603093) performance express: net profit in 2021 increased by 158% year-on-year
Nanhua Futures Co.Ltd(603093) release performance express. In 2021, the company achieved a total operating revenue of 10.515 billion yuan, a year-on-year increase of 6.05%; The net profit attributable to the shareholders of the listed company was 243 million yuan, with a year-on-year increase of 157.61%, mainly due to the year-on-year increase of the company’s brokerage service fee income, interest income and risk management business income.
Sailun Group Co.Ltd(601058) it is proposed to invest 1.426 billion yuan in Cambodia to build a project with an annual output of 1.65 million all steel radial tires
Sailun Group Co.Ltd(601058) announced that the company plans to invest in the construction of a project with an annual output of 1.65 million all steel radial tires in Cambodia, with a total investment of 1425.85 million yuan. The project is planned to be completed by cart Tire Co., a wholly-owned subsidiary of Sailun International Holdings (Hong Kong) Co., Ltd., a wholly-owned subsidiary of the company., Ltd is responsible for implementation.
Xuancheng Valin Precision Technology Co.Ltd(603356) shareholders plan to reduce their holdings of no more than 1.35% of the company’s shares
According to the announcement of Xuancheng Valin Precision Technology Co.Ltd(603356) , Xue Fei, a shareholder with a shareholding of 5.41%, plans to reduce the company’s shares by means of centralized bidding. It is expected that the total reduction will not exceed 1803500 shares, that is, 1.35% of the company’s total share capital.
Jiangsu Feymer Technology Co.Ltd(688350) it is proposed to repurchase shares of 50 million yuan to 100 million yuan
Jiangsu Feymer Technology Co.Ltd(688350) announced that the company plans to repurchase shares for employee stock ownership plan or equity incentive. The repurchase amount shall not be less than 50 million yuan and not more than 100 million yuan; The repurchase price shall not exceed 25 yuan / share.
On the same day, the company announced that ruishibang, a shareholder holding 8.89% of the shares, plans to reduce its Jiangsu Feymer Technology Co.Ltd(688350) shares by means of centralized bidding and block trading, not more than 3660000 shares, that is, not more than 3% of the total share capital of the company, within 6 months after 15 trading days from the date of disclosure of the reduction plan.
Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392) performance express: net profit in 2021 increased by 198% year-on-year
Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392) release performance express. In 2021, the company achieved an operating revenue of 5.75 billion yuan, a year-on-year increase of 144.25%; The net profit attributable to shareholders of listed companies was 2.016 billion yuan, a year-on-year increase of 197.83%; The net profit attributable to shareholders of listed companies after deducting non recurring profits and losses was 1.94 billion yuan, a year-on-year increase of 214.48%. The main factors affecting the business performance are that the company’s bivalent cervical cancer vaccine continues to maintain prosperous production and sales, and the revenue and profit increase at a high speed; Due to the substantial increase in overseas testing demand, the company’s covid-19 raw material sales and overseas testing reagent export revenue achieved rapid growth.
Keda Industrial Group Co.Ltd(600499) performance express: net profit in 2021 increased by 295% year-on-year
Keda Industrial Group Co.Ltd(600499) release performance express. In 2021, the company achieved an operating revenue of 9591015900 yuan, a year-on-year increase of 31.43%; The net profit attributable to the shareholders of the listed company was 1031.9026 million yuan, a year-on-year increase of 294.60%. During the reporting period, focusing on the strategy of high-end manufacturing and focusing on main business, the company actively promoted the development of various businesses and realized the steady growth of the company’s performance. Benefiting from the increase of production and sales volume and product price of Lanke lithium, the company’s investment income increased significantly.
Humanwell Healthcare (Group) Co.Ltd(600079) memantine hydrochloride sustained release capsule obtained the drug registration certificate
Humanwell Healthcare (Group) Co.Ltd(600079) announced that Yichang humanwell, the holding subsidiary of the company, recently received the drug registration certificate of memantine hydrochloride sustained-release capsule approved and issued by the State Food and drug administration. Memantine hydrochloride sustained release capsule is used to treat moderate to severe Alzheimer’s dementia.
